NSAIDs increase the risk of mucosal injuries but not of overt small bowel bleeding

Abstract

Since 2001, small bowel capsule endoscopy (SBCE) has been widely implemented into clinical practice as a minimal-invasive diagnostic approach for diagnosing small bowel diseases. Currently, SBCE is moreover recognized as the first-line procedure for the diagnostic work-up of obscure gastrointestinal bleeding (OGIB) and for a variety of SB disorders including Crohn's disease, inherited polyposis syndromes, suspected small bowel tumors or refractory celiac disease [1,2]. In addition, capsule endoscopy is used to guide the decision whether device assisted enteroscopy (i.e., balloon-assisted endoscopy; spiral enteroscopy) should be beneficial or not, thereby predicting the need of targeted biopsies, endoscopic therapies, and the preferred insertion route (i.e., oral or retrograde approach).

This article is protected by copyright. All rights reserved.

http://ift.tt/2ihwg4c